6.61
Schlusskurs vom Vortag:
$7.00
Offen:
$5.86
24-Stunden-Volumen:
134.37K
Relative Volume:
3.08
Marktkapitalisierung:
$611.37M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-4.4966
EPS:
-1.47
Netto-Cashflow:
$-38.94M
1W Leistung:
-19.02%
1M Leistung:
+10.17%
6M Leistung:
-8.55%
1J Leistung:
-90.88%
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Vergleichen Sie VRCA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VRCA
Verrica Pharmaceuticals Inc
|
6.61 | 64.74M | 5.12M | -67.00M | -38.94M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-07-25 | Hochstufung | Needham | Hold → Buy |
2023-03-22 | Eingeleitet | Jefferies | Buy |
2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
2020-06-24 | Eingeleitet | Northland Capital | Outperform |
2020-03-24 | Eingeleitet | Needham | Buy |
2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
What analysts say about Verrica Pharmaceuticals Inc. stockExceptional return forecasts - PrintWeekIndia
What drives Verrica Pharmaceuticals Inc. stock priceFree Stock Selection - PrintWeekIndia
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialFree Consultation - Newser
VRCA Trading Halted: Anticipation Builds for Pending Announcemen - GuruFocus
Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationRemarkably fast returns - jammulinksnews.com
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com
Is Verrica Pharmaceuticals Inc. a good long term investmentAccelerated earnings growth - jammulinksnews.com
Published on: 2025-07-19 07:38:47 - jammulinksnews.com
What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser
What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com
How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verrica Pharmaceuticals Inc-Aktie (VRCA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
26,183 |
69,647 |
115,303 |
Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
9,530 |
23,444 |
105,773 |
Goldenberg Gary | Chief Medical Officer |
Aug 26 '24 |
Sale |
2.66 |
9,888 |
26,302 |
97,862 |
Goldenberg Gary | Chief Medical Officer |
Aug 27 '24 |
Sale |
2.46 |
3,601 |
8,858 |
94,261 |
Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
24,709 |
65,726 |
82,107 |
Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
8,993 |
22,123 |
73,114 |
Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
21,820 |
58,041 |
52,596 |
Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
7,899 |
19,432 |
44,697 |
White Ted | PRESIDENT AND CEO |
Aug 26 '24 |
Sale |
2.66 |
24,979 |
66,444 |
224,988 |
White Ted | PRESIDENT AND CEO |
Aug 27 '24 |
Sale |
2.46 |
9,021 |
22,192 |
215,967 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):